Fertility preservation before an ABVD protocol: no new evidence to support changing the recommendations

Future Oncol. 2017 Mar;13(7):589-590. doi: 10.2217/fon-2016-0441. Epub 2016 Dec 6.

Authors

Catherine Poirot^{1

2}, Nathalie Dhedin¹, Pauline Brice³

Affiliations

¹ Service d'Hématologie, Unité AJA, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France.
² Université Paris VI, 4 place Jussieu, 75005 Paris, France.
³ Service d'Hématologie-Oncologie, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010 Paris, France.

PMID: 27921440
DOI: 10.2217/fon-2016-0441

No abstract available

Keywords: ABVD; Hodgkin lymphoma; fertility preservation.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bleomycin / adverse effects
Dacarbazine / adverse effects
Doxorubicin / adverse effects
Female
Fertility
Fertility Preservation* / methods
Hodgkin Disease / complications
Hodgkin Disease / drug therapy
Humans
Infertility / etiology
Oocyte Retrieval
Oocytes / drug effects
Vinblastine / adverse effects

Substances

Bleomycin
Vinblastine
Dacarbazine
Doxorubicin

Supplementary concepts

ABVD protocol